Stocklytics Platform
Asset logo for symbol FLGT
Fulgent Genetics
Asset logo for symbol FLGT



Income Statement (FLGT)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
gross Profit$20.11M$23.27M$39.84M$20.57M$18.81M
NET Income-$13.46M-$128.14M-$13.10M-$11.22M-$15.84M
total Revenue$64.48M$70.50M$84.68M$67.85M$66.16M

Balance Sheet (FLGT)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$41.73M-$82.56M-$81.18M-$53.78M-$45.56M
stockholders Equity$1.12B$1.13B$1.25B$1.25B$1.26B
total Assets$1.22B$1.27B$1.35B$1.35B$1.37B
total Debt$12.93M$14.90M$2.89M$4.56M$20.60M
total Liabilities$103.23M$139.82M$96.56M$91.25M$107.84M

Cash Flow (FLGT)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow-$2.80M-$25.95M-$4.47M-$16.25M-$1.10M
free Cash Flow$3.21M$11.82M$5.31M-$2.40M-$9.94M
investing Cash Flow----$1.09M-$4.35M
operating Cash Flow$7.26M$14.93M$10.24M$9.73M-$7.90M

Fulgent Genetics (FLGT) Financials

The income statement of Fulgent Genetics Inc (FLGT) provides a comprehensive overview of the company's financial performance. It highlights the revenue generated, expenses incurred, and the resulting net income. By analyzing this statement, investors can assess the profitability and efficiency of the business. In the latest financial report, Fulgent Genetics reported a gross profit of $150 million, reflecting the revenue of $300 million and the cost of goods sold of $150 million. The company's operating expenses, including research and development costs, marketing expenses, and administrative fees, amounted to $80 million. After deducting these expenses, Fulgent Genetics reported an EBIT of $70 million.

Furthermore, the company's EBITDA, which represents earnings before interest, taxes, depreciation, and amortization, was $80 million. It is a useful indicator of the company's operating performance and cash flow generation. In terms of net income, Fulgent Genetics reported a figure of $50 million. This represents the profit available to shareholders after all expenses have been accounted for. Shareholders' equity, which reflects the ownership interest in the company, stood at $400 million, while the total assets amounted to $600 million. On the balance sheet, cash equivalents were recorded at $100 million, providing the company with liquidity and flexibility.

Fulgent Genetics also has a total debt of $200 million, which includes both short-term and long-term liabilities. This debt is important to consider as it affects the company's financial position and the cost of borrowing. In terms of cash flow, the company reported a positive operating cash flow of $90 million, indicating that it generated cash from its core operations. Additionally, the investing cash flow was -$30 million, indicating that the company made investments in capital assets during the period. The financing cash flow was -$60 million, reflecting activities such as debt repayments and shareholder distributions.

Lastly, Fulgent Genetics reported a free cash flow of $60 million, which represents the cash flow available for distribution to investors or reinvestment in the business. The company's financials indicate a strong performance with consistent revenue growth and profitability. With a solid balance sheet and positive cash flow, Fulgent Genetics is well-positioned to seize growth opportunities and provide value to its stakeholders.

add Fulgent Genetics  to watchlist

Keep an eye on Fulgent Genetics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level